EUCTR2017-002429-39-SI进行中（未招募）1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE - LeoDOR
Medical University Innsbruck0 个研究点目标入组 264 人开始时间: 2018年7月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written, signed and dated informed consent.
- •2.Male and female patients over 18 years of age.
- •3.Women of childbearing potential must have a monthly negative pregnancy test and must refrain from breastfeeding. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be of childbearing potential.
- •4.CHF diagnosed at least 6 months before screening and treated with individually optimised long-term oral treatment for the last month, unless not tolerated (e.g., ACE-inhibitor or AT II blocker, beta-blocker, mineralocorticoid receptor antagonist, angiotensin II receptor blocker neprilysin inhibitor [ARNI] and with devices [e.g., CRT/ICD], as needed).
- •5.Left ventricular ejection fraction less than or equal to 35% as assessed using echocardiography, radionuclide ventriculography or contrast angiography within the index hospitalisation.
- •6.Currently hospitalised for decompensated HF requiring i.v. diuretics, or i.v. vasodilators, or i.v. inotropic therapy, or their combination.
- •7.Previous hospitalisation or visit to outpatient clinic requiring i.v. diuretics, i.v. vasodilators, or i.v. inotropic therapy, or their combination for acute decompensated HF within 12 months before the current hospitalisation.
- •8.NT-proBNP level after recompensation (= haemodynamically stable euvolemic, established on evidence-based oral medication and with stable renal function for at least 24hrs before discharge) in patients in sinus rhythm of =2000ng/L (BNP =600mg/L), in patients in atrial fibrillation of =2500 ng/L (BNP =900 ng/L) and/or NYHA class III or IV at study entry.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 52
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 212
排除标准
- •1.Severe obstruction of ventricular outflow tracts such as haemodynamically significant uncorrected primary valve disease or hypertrophic cardiomyopathy or impaired ventricular filling such as restrictive cardiomyopathy.
- •2.Predominantly right heart failure and/or severe tricuspid regurgitation
- •3.Cardiac surgery or coronary angioplasty within 30 days before study drug initiation.
- •4.Acute coronary syndrome within 30 days before study drug initiation.
- •5.Patients who are scheduled for cardiac surgery or angioplasty in the next 3 months.
- •6.History of torsades de pointes.
- •7.Stroke or transient ischaemic attack (TIA) within 3 months before study drug initiation.
- •8.Systolic blood pressure less than 90 mmHg at baseline.
- •9.Heart rate 120 bpm or greater at baseline.
- •10.Serum potassium less than 3.5 mmol/l before study drug initiation.
- •11.Severe renal insufficiency (estimated glomerular filtration rate [eGFR] less than 30 ml/min/1.73m2).
- •12.Anaemia (haemoglobin less than 10 g/dl).
- •13.Significant hepatic impairment at discretion of the investigator.
- •14.Hypersensitivity to levosimendan.
- •15.Other serious diseases limiting life expectancy considerably (e.g. end-stage cancer, end-stage renal disease, end-stage lung disease).
- •16.Participation in a clinical trial with any experimental treatment within 30 days prior to screening or previous participation in the present study.
- •17.Administration of levosimendan within 14 days prior the study drug initiation. (The first study drug application has to be postponed for at least 14 days after the end of this premedication)
- •18.Suspected non-compliance
- •19.Pregnant women and nursing mothers
- •20.Failure to use highly effective (a Pearl Index lower than 1%) contraceptive methods.
- •21.Persons with any kind of dependency on the investigator
- •22.Persons held in an institution by legal or official order
研究者
相似试验
进行中（未招募）
1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILUREAdvanced chronic heart failureEUCTR2017-002429-39-FIMedical University Innsbruck264
进行中（未招募）
1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILUREAdvanced chronic heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2017-002429-39-DKMedical University Innsbruck264
进行中（未招募）
1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILUREAdvanced chronic heart failureEUCTR2017-002429-39-HUMedical University Innsbruck264
进行中（未招募）
1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILUREAdvanced chronic heart failureEUCTR2017-002429-39-DEMedical University Innsbruck264
进行中（未招募）
1 期
REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILUREAdvanced chronic heart failureEUCTR2017-002429-39-ATMedical University Innsbruck264